Is Eli Lilly Stock Outperforming the Nasdaq?

With a market capitalization of $1 trillion, Eli Lilly and Company (LLY) is a global pharmaceutical company focused on developing and commercializing medicines across areas such as diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular disease. Founded in 1876 and headquartered in Indianapolis, Indiana, the company is one of the world’s largest drugmakers and is widely recognized for its leadership in diabetes and weight-loss treatments.

Companies worth $200 billion or more are generally classified as “mega-cap stocks,” and Eli Lilly firmly fits that category, with its market capitalization well above this threshold. The company’s massive valuation reflects its strong influence and leadership within the global pharmaceutical industry, particularly in the rapidly expanding diabetes and obesity treatment markets driven by blockbuster drugs such as Mounjaro and Zepbound.